Imrecoxib and Celecoxib Affect Sacroiliac Joint Inflammation in AxSpA by Regulating Bone Metabolism and Angiogenesis

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2023 Feb 17

PMID 36800138

Authors

Yanke Guo

Dongbin Jiang

Zhiyan Mai

Yufeng Chen

Ting Li

Guanmin Gao

Affiliations

Soon will be listed here.

Abstract

Objective: To analyze the changes in the levels of bone metabolism markers related to sacroiliac joint (SIJ) inflammation in patients with axial spondyloarthritis (axSpA) after treatment with imrecoxib and celecoxib and evaluate their relationship with clinical efficacy.

Methods: A total of 120 patients with axSpA with at least 2 magnetic resonance imaging (MRI) SIJ scans during a 12-week follow-up were enrolled. The levels of bone metabolism markers, including dickkopf-1(DKK-1), sclerostin, vascular endothelial growth factor (VEGF), bone morphogenetic protein-2 (BMP-2), osteoprotegerin (OPG), noggin, β-catenin, and RUNX2, were measured twice, and their association with disease activity and the Spondyloarthritis Research Consortium of Canada (SPARCC) score for SIJ were analyzed by univariate analysis of covariance.

Results: A total of 116 patients completed the follow-up. The levels of sclerostin, OPG, noggin, DKK-1, and RUNX2 were increased, whereas those of VEGF and β-catenin were decreased. The levels of sclerostin and OPG were negatively correlated with disease duration. The levels of VEGF and β-catenin were significantly decreased (F = 7.866, P = 0.003; F = 4.106, P = 0.047) in patients with disease remission. A decrease in ESR was significantly correlated with decreased levels of Runx2 and SPARCC scores, with the levels of sclerostin being significantly elevated in the SPARCC-reduced group. There were no statistically significant differences between the imrecoxib and celecoxib groups (P> 0.05).

Conclusion: Imrecoxib and celecoxib affect SIJ inflammation, disease activity, and the course of disease by regulating bone metabolism and angiogenesis in axSpA. Key Points •After treatment with imrecoxib and celecoxib, the levels of sclerostin, OPG, noggin, DKK-1, and RUNX2 were increased, whereas those of VEGF and β-catenin were decreased, correlating with the course of disease, disease activity, and SIJ inflammation. • A decrease in ESR was significantly correlated with a decrease in the levels of RUNX2 and SIJ inflammation.. • The levels of sclerostin were more significantly elevated in SIJ inflammation remission group.. •Imrecoxib and celecoxib affect SIJ inflammation by regulating bone metabolism and angiogenesis in axSpA..

Citing Articles

The serum level of sclerostin decreases in radiographic axial spondyloarthritis patients with fatty lesions.

Li X, Jiang H, Wang X, Zhong S Arthritis Res Ther. 2025; 27(1):10.

PMID: 39825398 PMC: 11740347. DOI: 10.1186/s13075-025-03479-x.

Imrecoxib: Advances in Pharmacology and Therapeutics.

Wang Y, Zhu L, Li T, Zhou Q Drug Des Devel Ther. 2024; 18:1711-1725.

PMID: 38799798 PMC: 11128231. DOI: 10.2147/DDDT.S464485.

Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study.

Zhang K, Miao X, Jiang L, Cui S, Liu Z, Wang Z Inflammopharmacology. 2023; 31(4):1813-1822.

PMID: 37306938 DOI: 10.1007/s10787-023-01260-7.

References

Sieper J, Braun J, Dougados M, Baeten D . Axial spondyloarthritis. Nat Rev Dis Primers. 2016; 1:15013. DOI: 10.1038/nrdp.2015.13. View

Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou C . The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2010; 70(1):25-31. DOI: 10.1136/ard.2010.133645. View

Aouad K, Ziade N, Baraliakos X . Structural progression in axial spondyloarthritis. Joint Bone Spine. 2019; 87(2):131-136. DOI: 10.1016/j.jbspin.2019.04.006. View

Sieper J, Poddubnyy D . Axial spondyloarthritis. Lancet. 2017; 390(10089):73-84. DOI: 10.1016/S0140-6736(16)31591-4. View

Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J . The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther. 2008; 10(5):R104. PMC: 2592781. DOI: 10.1186/ar2496. View

Bonewald L, Johnson M . Osteocytes, mechanosensing and Wnt signaling. Bone. 2008; 42(4):606-15. PMC: 2349095. DOI: 10.1016/j.bone.2007.12.224. View

Xie W, Zhou L, Li S, Hui T, Chen D . Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis. Ann N Y Acad Sci. 2015; 1364:25-31. PMC: 4803629. DOI: 10.1111/nyas.12968. View

Furst D, Louie J . Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Res Ther. 2019; 21(1):135. PMC: 6549293. DOI: 10.1186/s13075-019-1885-z. View

Zhao Z, Wang G, Wang Y, Yang J, Wang Y, Zhu J . Correlation between magnetic resonance imaging (MRI) findings and the new bone formation factor Dkk-1 in patients with spondyloarthritis. Clin Rheumatol. 2018; 38(2):465-475. DOI: 10.1007/s10067-018-4284-y. View

10.

Nagy V, Penninger J . The RANKL-RANK Story. Gerontology. 2015; 61(6):534-42. DOI: 10.1159/000371845. View

11.

Xiao Y, Xiang L, Shao J . Bone morphogenetic protein. Biochem Biophys Res Commun. 2007; 362(3):550-3. DOI: 10.1016/j.bbrc.2007.08.045. View

12.

Rahman M, Akhtar N, Jamil H, Banik R, Asaduzzaman S . TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation. Bone Res. 2015; 3:15005. PMC: 4472151. DOI: 10.1038/boneres.2015.5. View

13.

Xie Z, Wang P, Li Y, Deng W, Zhang X, Su H . Imbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal Osteogenic Differentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis. Arthritis Rheumatol. 2015; 68(2):430-40. DOI: 10.1002/art.39433. View

14.

Dai J, Rabie A . VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res. 2007; 86(10):937-50. DOI: 10.1177/154405910708601006. View

15.

Braun J, Baraliakos X, Hermann K, Xu S, Hsu B . Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab. J Rheumatol. 2016; 43(5):901-6. DOI: 10.3899/jrheum.150897. View

16.

Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landewe R . Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017; 3(1):e000397. PMC: 5278330. DOI: 10.1136/rmdopen-2016-000397. View

17.

Nagano A, Arioka M, Takahashi-Yanaga F, Matsuzaki E, Sasaguri T . Celecoxib inhibits osteoblast maturation by suppressing the expression of Wnt target genes. J Pharmacol Sci. 2016; 133(1):18-24. DOI: 10.1016/j.jphs.2016.11.003. View

18.

Wanders A, van der Heijde D, Landewe R, Behier J, Calin A, Olivieri I . Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005; 52(6):1756-65. DOI: 10.1002/art.21054. View

19.

Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H . Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012; 71(10):1616-22. DOI: 10.1136/annrheumdis-2011-201252. View

20.

Moreno-Rubio J, Herrero-Beaumont G, Tardio L, Alvarez-Soria M, Largo R . Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. Arthritis Rheum. 2010; 62(2):478-88. DOI: 10.1002/art.27204. View